Ardelyx Inc (ARDX)
8.72
+1.93
(+28.42%)
USD |
NASDAQ |
May 03, 16:00
8.70
-0.02
(-0.23%)
After-Hours: 20:00
Ardelyx Enterprise Value: 1.895B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.895B |
| May 02, 2024 | 1.445B |
| May 01, 2024 | 1.404B |
| April 30, 2024 | 1.355B |
| April 29, 2024 | 1.369B |
| April 26, 2024 | 1.359B |
| April 25, 2024 | 1.334B |
| April 24, 2024 | 1.362B |
| April 23, 2024 | 1.352B |
| April 22, 2024 | 1.380B |
| April 19, 2024 | 1.373B |
| April 18, 2024 | 1.364B |
| April 17, 2024 | 1.390B |
| April 16, 2024 | 1.427B |
| April 15, 2024 | 1.448B |
| April 12, 2024 | 1.508B |
| April 11, 2024 | 1.580B |
| April 10, 2024 | 1.525B |
| April 09, 2024 | 1.534B |
| April 08, 2024 | 1.569B |
| April 05, 2024 | 1.611B |
| April 04, 2024 | 1.532B |
| April 03, 2024 | 1.576B |
| April 02, 2024 | 1.573B |
| April 01, 2024 | 1.590B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.564B |
| March 27, 2024 | 1.590B |
| March 26, 2024 | 1.592B |
| March 25, 2024 | 1.657B |
| March 22, 2024 | 1.657B |
| March 21, 2024 | 1.687B |
| March 20, 2024 | 1.680B |
| March 19, 2024 | 1.732B |
| March 18, 2024 | 1.690B |
| March 15, 2024 | 1.750B |
| March 14, 2024 | 1.734B |
| March 13, 2024 | 1.876B |
| March 12, 2024 | 1.825B |
| March 11, 2024 | 1.841B |
| March 08, 2024 | 1.888B |
| March 07, 2024 | 1.953B |
| March 06, 2024 | 2.083B |
| March 05, 2024 | 2.097B |
| March 04, 2024 | 1.969B |
| March 01, 2024 | 2.039B |
| February 29, 2024 | 2.034B |
| February 28, 2024 | 2.067B |
| February 27, 2024 | 2.116B |
| February 26, 2024 | 2.027B |
| February 23, 2024 | 1.885B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.3966M
Minimum
Feb 23 2022
2.130B
Maximum
Feb 09 2024
467.26M
Average
407.79M
Median
Jan 13 2020
Enterprise Value Benchmarks
| Nektar Therapeutics | -15.34M |
| Rigel Pharmaceuticals Inc | 213.12M |
| Omeros Corp | 257.43M |
| Vistagen Therapeutics Inc | -4.946M |
| Karyopharm Therapeutics Inc | 109.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.80M |
| Revenue (Quarterly) | 34.36M |
| Total Expenses (Quarterly) | 62.35M |
| EPS Diluted (Quarterly) | -0.13 |
| Gross Profit Margin (Quarterly) | 85.23% |
| Profit Margin (Quarterly) | -83.82% |
| Earnings Yield | -3.56% |
| Normalized Earnings Yield | -3.555 |